Viewing Study NCT01018069

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:50 PM
Ignite Modification Date: 2026-01-01 @ 11:18 PM
Study NCT ID: NCT01018069
Status: TERMINATED
Last Update Posted: 2011-07-13
First Post: 2009-11-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Sponsor: Aegera Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute View
None myeloid View
None leukemia View
None antisense View
None chemotherapy View
None idarubicin View
None cytarabine View
None Patients with AML, except those with APL (acute promyelocytic leukemia), … View